Literature DB >> 19830215

Prosthetic valve endocarditis caused by Candida lusitaniae, an uncommon pathogen: a case report.

Ross G Michel, Gary T Kinasewitz, Douglas A Drevets, Jeremy H Levin, Douglas W Warden.   

Abstract

INTRODUCTION: Candida lusitaniae was originally described as a human pathogen in 1979 and typically affects immunocompromised patients. CASE
PRESENTATION: We describe a case of prosthetic valve endocarditis with Candida lusitaniae in an immunocompetent 62-year-old woman following aortic valve replacement. In vitro testing demonstrated that our isolate was sensitive to amphotericin B, caspofungin and fluconazole.
CONCLUSION: The infection was lethal despite aggressive medical and surgical management and sterilization of blood cultures. The outcome of our case illustrates the need to recognize Candida lusitaniae fungemia as a life-threatening infection in a patient with a prosthetic aortic valve.

Entities:  

Year:  2009        PMID: 19830215      PMCID: PMC2726537          DOI: 10.1186/1752-1947-3-7611

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


Introduction

Candida species are the most frequent causes of fungal endocarditis. Mortality from Candida endocarditis has been reported at a rate of 50-80% [1]. Candida albicans is the most frequently isolated species, followed by C. parapsilosis, C. glabrata and C. tropicalis. C. lusitaniae, originally described as a human pathogen in 1979, typically affects immunocompromised patients and accounts for less than 5% of all invasive Candida infections [2,3]. Infections including meningitis, osteomyelitis and peritonitis have been reported, but the most common presentation of this pathogen is fungemia in patients undergoing chemotherapy for cancer [4]-[6]. Prosthetic valve endocarditis with this organism has been described only once previously [7]. Although resistance to amphotericin B has been reported, a recent susceptibility study has shown that the majority of C. lusitaniae isolates are flucytosine resistant and amphotericin-B susceptible [8]. In contrast, in vitro testing of the isolate in this case demonstrated sensitivity to amphotericin B, caspofungin and fluconazole.

Case presentation

A 62-year-old Caucasian woman presented with a two-month history of intermittent fever. Her past medical history included hypertension, dyslipidema, coronary artery disease and mild chronic kidney disease. She was found to have Enterococcus faecalis endocarditis of her native, bicuspid, aortic valve. She was treated with vancomycin, gentamicin and penicillin and subsequently underwent aortic valve replacement (AVR) with a Saint Jude valve in October of 2004. Her postoperative course was complicated by evacuation of a mediastinal hematoma, splenectomy and a partial colectomy with diverting colostomy for hemorrhagic colitis. The patient had been discharged and re-admitted multiple times and was ultimately transferred to the Oklahoma University Medical Center in May 2005. Upon transfer, the patient complained of dyspnea, orthopnea and lower-extremity swelling. She was afebrile and hemodynamically stable. Her physical examination revealed jugular venous distention, a III/VI systolic murmur in the right second intercostal space, and bilateral lower-extremity edema to the knees. No peripheral stigmata of endocarditis were identified. Nine blood cultures obtained over a five-day period were positive for Candida lusitaniae. Susceptibility testing was performed on the initial isolate only and revealed sensitivity to amphotericin B, caspofungin and fluconazole (Table 1). Transesophageal echocardiography revealed multiple vegetations on a partially dehiscent mechanical aortic valve (Figure 1) with severe aortic valvular regurgitation and a left ventricular ejection fraction of 50% (Figure 2). Therapy with caspofungin was initiated prior to obtaining results of susceptibility testing on the initial isolate and was continued based on the minimal inhibitory concentration (MIC). The patient eventually underwent repeat AVR with coronary artery bypass grafting. Vegetations were noted on her removed prosthetic valve (Figures 3 and 4). Her post-operative course was complicated by a chest hematoma which was evacuated. Despite eventual clearance of her fungemia, the patient died from multi-organ failure in June 2005.
Table 1

MICs and minimum fungicidal concentrations for Candida lusitaniae isolate from May 2005

AgentParameter, value (mcg/mL)
Amphotericin BMIC 0.50
MFC 0.50
CaspofunginMIC 0.06
MFC ND
FluconazoleMIC 0.25
MFC ND

Note: Susceptibility of blood culture isolate to Caspofungin performed by the Fungus Testing Lab, UTHSC, San Antonio, TX. All other susceptibilities of blood culture isolate were determined by Microbiology Laboratory at OU Medical Center, Oklahoma City, OK.

MFC = minimum fungicidal concentration. ND = Not done.

Figure 1

Trans-esophageal echocardiographic image of prosthetic aortic valve vegetations. White arrow indicates largest fungal vegetation identified in this case.

Figure 2

Infected prosthetic aortic valve regurgitation. Trans-esophageal echocardiography was helpful in identification of the prosthetic valve infection and dysfunction.

Figure 3

Infected prosthetic aortic valve. Notice the irregularities on the leaflet surfaces of the removed prosthetic valve.

Figure 4

Prosthetic aortic valve vegetation. Black arrow indicates a vegetation on the removed prosthetic valve.

MICs and minimum fungicidal concentrations for Candida lusitaniae isolate from May 2005 Note: Susceptibility of blood culture isolate to Caspofungin performed by the Fungus Testing Lab, UTHSC, San Antonio, TX. All other susceptibilities of blood culture isolate were determined by Microbiology Laboratory at OU Medical Center, Oklahoma City, OK. MFC = minimum fungicidal concentration. ND = Not done. Trans-esophageal echocardiographic image of prosthetic aortic valve vegetations. White arrow indicates largest fungal vegetation identified in this case. Infected prosthetic aortic valve regurgitation. Trans-esophageal echocardiography was helpful in identification of the prosthetic valve infection and dysfunction. Infected prosthetic aortic valve. Notice the irregularities on the leaflet surfaces of the removed prosthetic valve. Prosthetic aortic valve vegetation. Black arrow indicates a vegetation on the removed prosthetic valve.

Discussion

It remains unknown whether the source of our patient's fungemia was her abdominal surgery or a central venous catheter infection. Transesophageal echocardiography was helpful in identifying prosthetic valve infection and dysfunction. MIC testing of the initial fungal isolate demonstrated susceptibility to multiple antifungals. Potential biofilm formation on the prosthetic valve could have resulted in a discrepancy between the MIC derived from the blood isolate and the isolate at the site of infection, although the latter was not submitted for testing. Aggressive surgical management and antifungal treatment led to clearance of our patient's fungemia. Nevertheless, the infection resulted in a lethal outcome as in the previously described case [7]. The shared outcome of our case with that of the previous case clearly illustrates the need to recognize Candida lusitaniae fungemia as a life-threatening infection in a patient with a prosthetic aortic valve.

Conclusion

We describe a case of prosthetic valve endocarditis with Candida lusitaniae following AVR in an immunocompetent patient. To our knowledge, this is only the second reported case of prosthetic valve endocarditis due to this uncommon Candida species. In vitro testing demonstrated that our isolate was sensitive to amphotericin B, caspofungin and fluconazole. As in the previously described case, this infection was lethal despite aggressive medical and surgical management and sterilization of blood cultures.

Consent

Written informed consent was obtained from the patient's next-of-kin for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Author's contributions

All authors have made substantial contributions to the case presentation and discussion, have been involved in drafting the manuscript or revising it critically for important intellectual content and have given final approval of the version to be published.
  8 in total

1.  Candida lusitaniae: an uncommon cause of prosthetic valve endocarditis.

Authors:  B Wendt; L Haglund; A Razavi; R Rath
Journal:  Clin Infect Dis       Date:  1998-03       Impact factor: 9.079

Review 2.  Invasive candidiasis in the intensive care unit.

Authors:  Luis Ostrosky-Zeichner; Peter G Pappas
Journal:  Crit Care Med       Date:  2006-03       Impact factor: 7.598

Review 3.  Mycoses caused by Candida lusitaniae.

Authors:  T L Hadfield; M B Smith; R E Winn; M G Rinaldi; C Guerra
Journal:  Rev Infect Dis       Date:  1987 Sep-Oct

4.  Development of resistance to amphotericin B in Candida lusitaniae infecting a human.

Authors:  D Pappagianis; M S Collins; R Hector; J Remington
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.

Authors:  Anne Favel; Annie Michel-Nguyen; Annick Datry; Svetlana Challier; Florence Leclerc; Christiane Chastin; Karim Fallague; Patrick Regli
Journal:  J Antimicrob Chemother       Date:  2004-02-12       Impact factor: 5.790

6.  Candida endocarditis: contemporary cases from the International Collaboration of Infectious Endocarditis Merged Database (ICE-mD).

Authors:  Daniel K Benjamin; Jose M Miro; Bruno Hoen; William J Steinbach; Vance G Fowler; Lars Olaison; Gilbert Habib; Elias Abrutyn; John Perfect; Amy Zass; G Ralph Corey; Susannah Eykyn; Franck Thuny; María-Jesús Jiménez-Expósito; Christopher H Cabell
Journal:  Scand J Infect Dis       Date:  2004

Review 7.  Emergence of a new opportunistic pathogen, Candida lusitaniae.

Authors:  R J Blinkhorn; D Adelstein; P J Spagnuolo
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

Review 8.  Candida lusitaniae infections in the era of fluconazole availability.

Authors:  Jimmy L Hawkins; Larry M Baddour
Journal:  Clin Infect Dis       Date:  2003-01-03       Impact factor: 9.079

  8 in total
  6 in total

1.  Usefulness of McRAPD for typing and importance of biofilm production in a case of nosocomial ventriculoperitoneal shunt infection caused by Candida lusitaniae.

Authors:  Petr Hamal; Juraj Hanzen; Frantisek Horn; Jitka Trtkova; Lenka Ruskova; Renata Vecerova; Filip Ruzicka; Anna Vollekova; Vladislav Raclavsky
Journal:  Folia Microbiol (Praha)       Date:  2011-09-06       Impact factor: 2.099

Review 2.  Fungal endocarditis observed over an 8-year period and a review of the literature.

Authors:  Spinello Antinori; Laurenzia Ferraris; Giovanna Orlando; Loredana Tocalli; Davide Ricaboni; Mario Corbellino; Salvatore Sollima; Massimo Galli; Laura Milazzo
Journal:  Mycopathologia       Date:  2014-06-26       Impact factor: 2.574

3.  Balancing Positive and Negative Selection: In Vivo Evolution of Candida lusitaniae MRR1.

Authors:  Elora G Demers; Jason E Stajich; Alix Ashare; Patricia Occhipinti; Deborah A Hogan
Journal:  mBio       Date:  2021-03-30       Impact factor: 7.867

4.  Disseminated Candida lusitaniae: Nosocomial Acquisition Secondary to an Indwelling Urinary Catheter.

Authors:  Ali Raja; Julia Park
Journal:  Case Rep Infect Dis       Date:  2021-06-17

5.  Analysis of Lung Microbiota in Bronchoalveolar Lavage, Protected Brush and Sputum Samples from Subjects with Mild-To-Moderate Cystic Fibrosis Lung Disease.

Authors:  Deborah A Hogan; Sven D Willger; Emily L Dolben; Thomas H Hampton; Bruce A Stanton; Hilary G Morrison; Mitchell L Sogin; Julianna Czum; Alix Ashare
Journal:  PLoS One       Date:  2016-03-04       Impact factor: 3.240

6.  A budding case of infectious endocarditis: Candida lusitaniae.

Authors:  Elham Rahmati; Adrian J Correa; Rosemary C She
Journal:  IDCases       Date:  2019-12-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.